Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 5, Issue 2, Pages 160-170Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd1958
Keywords
-
Ask authors/readers for more resources
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-d-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca2+ influx through the receptor's associated ion channel and consequent free-radical formation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available